Multicomponent therapy in patients with pelvic inflammatory diseases

Sukhanov A.A., Karakhalis L.Yu., Kukarskaya I.I., Baranov I.I.

1 Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia, Moscow, Russia; 2 Perinatal Center, Tyumen Region; 3 Territorial Clinical Hospital Two, Ministry of Health of the Krasnodar Territory
Objective. To compare the outcomes of combination therapy in patients with pelvic inflammatory diseases (PID) who use Longidase (Bovhyaluronidase azoximer) with those of therapy in patients who do not use of this drug.
Subjects and methods. An open-label multicenter comparative study was conducted in 240 patients with acute or exacerbated chronic PID. Group 1 of 170 women used Longidasa (Bovhyaluronidase azoximer) 3000-IU suppository once every 3 days in the combination therapy of PID with a total cycle of 20 administrations. Group 2 (n = 70) received basic therapy.
Results. In Group 1, lower abdominal pain syndrome was relieved much faster and detected in a larger number of patients: only 11 (6.5%) women in the study group continued to notice it after 2 months of treatment while there were 56 (80%) women in Group 2 (p < 0.001). Tenderness was reduced by palpation and cervical traction in all (100%) patients in the study group, while this symptom continued to be noted by 25.7% of women in the basic therapy group (p < 0.001). After performed therapy, the proportion of patients who were observed to have increased uterine dimensions decreased by 56% in Group 1 and only by 15.7% in Group 2 (p < 0.001). During 2-month follow-up, the number of patients with normal white blood cell counts in the cervical canal smear increased more than 3-fold in the study group, whereas 1.03-fold from the baseline in Group 2, and by the end of the follow-up, this was noted in 170 (100%) and 59 (84.3%) patients in Groups 1 and 2, respectively.
Conclusion. Longidasa (Bovhyaluronidase azoximer) increases the efficiency of combination treatment for PID, contributes to early improvement of the clinical status of patients, making appropriate use of the drug since the cycle of antibacterial therapy is initiated.


pelvic inflammatory diseases


1. Workowski K.A., Berman S.; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines. MMWR Recomm. Rep. 2010; 59(RR-12): 1-110.

2. Bugg C.W., Taira T., Zaurova M. Pelvic inflammatory disease: diagnosis and treatment in the emergency department [digest]. Emerg. Med. Pract. 2016; 1(12, Suppl. Points & Pearls): S1-2.

3. Синчихин С.П., Мамиев О.Б., Степанян Л.В., Эльдерова К.С., Магакян О.Г. Некоторые современные аспекты воспалительных заболеваний органов малого таза. Consilium medicum. 2015; 17(6): 73-6. [Sinchikhin S.P., Mamiev O.B, Stepanyan L.V., Elderova K.S., Magakyan O.G. Some modern aspects of inflammatory diseases of the pelvic organs. Consilium medicum. 2015; 17 (6): 73-6. (in Russian)]

4. Линева О.И., Шатунова Е.П., Коханова М.А. Патологоиммунологические аспекты развития хронического сальпингоофорита и пути их коррекции. Русский медицинский журнал. 2006; 14(18): 1301-3. [Lineva OI, Shatunova E.P., Kokhanova M.A. Pathological and immunological aspects of the development of chronic salpingoophoritis and ways to correct them. Russian medical journal. 2006; 14 (18): 1301-3. (in Russian)]

5. Гаспаров А.С., Дубинская Е.Д. Тазовые перитонеальные спайки: этиология, патогенез, диагностика, профилактика. М.: МИА; 2013. 168с. [Gasparov A.S., Dubinsky E.D. Pelvic peritoneal adhesions: etiology, pathogenesis, diagnosis, prevention. M .: MIA; 2013. 168p. (in Russian)]

6. Хабриев Р.У., Камаев Н.О., Данилова Т.И., Кахоян Е.Г. Особенности действия гиалуронидаз различного происхождения на соединительную ткань. Биомедицинская химия. 2016; 62(1): 82-8. [Khabriev, R.U., Kamaev, N.O., Danilova, T.I., Kakhoyan, E.G. Features of the action of hyaluronidase of different origin on connective tissue. Biomedical chemistry. 2016; 62 (1): 82-8. (in Russian)]

7. Инструкция по медицинскому применению лекарственного препарата Лонгидаза суппозитории вагинальные и ректальные. ЛСР-002940/07. 2016.

8. Петрович Е.А., Колесов А.А., Манухин И.Б. Безопасность и эффективность препарата Лонгидаза при спаечном процессе в малом тазу у гинекологических больных. Иммунология. 2006; 27(2): 124-6. [Petrovich E.A., Kolesov A.A., Manukhin I.B. The safety and efficacy of the drug Longidase in adhesions in the pelvis in gynecological patients. Immunology. 2006; 27 (2): 124-6. (in Russian)]

9. Некрасов А.В., Пучкова Н.Г., Карапутадзе Н.Т. Физико-химические принципы создания Лонгидазы. Иммунология. 2006; 27(2): 114-8. [Nekrasov A.V., Puchkova N.G., Karaputadze N.T. Physico-chemical principles of creating Longidase. Immunology. 2006; 27 (2): 114-8. (in Russian)]

10. Сулима А.Н., Давыдова А.А., Рыбалка А.Н., Беглицэ Д.А., Баскаков П.Н. Особенности профилактики и лечения спаечного процесса у пациенток с хроническими воспалительными заболеваниями органов малого таза. Consilium medicum. 2018; 20(1): 62-7. [Sulima A.N., Davydova A.A., Rybalka A.N., Beglitse D.A., Baskakov P.N. Features of prevention and treatment of adhesions in patients with chronic inflammatory diseases of the pelvic organs. Consilium medicum. 2018; 20 (1): 62-7. (in Russian)]

11. Дубровина С.О. Cпаечный процесс. М.: «Компания БОРГЕС»; 2015. 76с. [Dubrovina S.O. Sponge process. M.: “Company BORGES”; 2015. 76p. (in Russian)]

Received 26.11.2018

Accepted 07.12.2018

About the Authors

Sukhanov, Anton A., head of the Department of Family Planning and Reproduction Tyumen Perinatal Center, a graduate student of the Department of Obstetrics, Gynecology and Reanimatology with a course of clinical laboratory diagnostics of the Institute of Scientific and Technological Research of the State Budgetary Educational Institution of Higher Professional Education Tyumen State Medical University of the Russian Ministry of Health.
625002, Russia, Tyumen, Daudelnaya str. 1. Tel.: +7345250-82-77. E-mail:
Karakhalis, Lyudmila Yu., MD, professor of the Department of Obstetrics, Gynecology and Perinatology of the Faculty of Physical Education and Pedagogical Faculty of the State Educational Institution of Higher Education of the Kuban State Medical University of the Ministry of Health of Russia.
350063, Russia, Krasnodar, Mitrofan Sedin str. 4. Tel.: +7988 2444044. E-mail:
Kukarskaya, Irina I., MD, senior specialist in Obstetrics and Gynecology of the Department of Health of the Tyumen Region, Professor of the Department of Obstetrics, Gynecology and Resuscitation with a course of clinical laboratory diagnostics of the Institute of Hydrometeorological Education of Tyumen State Medical University of the Ministry of Health of the Russian Federation, Head Doctor of State Healthcare Institute Perinatalny Centre.
625002, Russia, Tyumen, Daudelnaya str. 1. Tel.: +73452508277. E-mail:
Baranov, Igor I., MD, professor, head of the Organizational and Methodological Department of the Federal State Budget Institution National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov of the Ministry of Healthcare of Russian Federation.
117997, Russia, Moscow, Academician Oparina str. 4. Tel.: +74954389492. E-mail:

For citations: Sukhanov A.A., Karakhalis L.Yu., Kukarskaya I.I., Baranov I.I. Multicomponent therapy in patients with pelvic inflammatory diseases. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2018; (12): 125-30. (in Russian)

Similar Articles

By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.